Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Laura Mettivier
Observed names:
L Mettivier,
L. Mettivier,
METTIVIER L
Institutions:
University of Salerno,
AOU San Giovanni di Dio e Ruggi d'Aragona
Observed institutions:
University of Salerno,
Ospedale Antonio Cardarelli,
AOU San Giovanni di Dio e Ruggi d'Aragona,
Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"
ORCID:
0000-0003-1473-7487
Observed ORCID:
0000-0003-1473-7487
OpenAlex ID:
A5083031946
Real-world evidence of cytomegalovirus reactivation in non-Hodgkin lymphomas treated with bendamustine-containing regimens
2021
·
Luca Pezzullo
, Valentina Giudice
, et al.
·
Open Medicine
·
17
PDF
Implementation of International Prognostic Index with flow cytometry immunophenotyping for better risk stratification of chronic lymphocytic leukemia
2022
·
Valentina Giudice
, Bianca Serio
, et al.
·
European Journal Of Haematology
·
15
Serum Free Light-Chain Ratio at Diagnosis Is Associated with Early Renal Damage in Multiple Myeloma: A Case Series Real-World Study
2022
·
Danilo De Novellis
, Raffaele Fontana
, et al.
·
Biomedicines
·
15
PDF
Prophylactic letermovir decreases cytomegalovirus reactivation after stem cell transplantation: a single-center real-world evidence study.
2021
·
Bianca Serio
, Valentina Giudice
, et al.
·
PubMed
·
11
Safety of Subcutaneous Daratumumab in Anti-CD38 Monoclonal Antibody-Naïve Patients with Plasma Cell Disorders: A Multicenter Real-Life Experience
2023
·
Danilo De Novellis
, Raffaele Fontana
, et al.
·
Targeted Oncology
·
6
PDF
Tuning the B-CLL microenvironment: evidence for BAG3 protein- mediated regulation of stromal fibroblasts activity
2024
·
Anna Basile
, Valentina Giudice
, et al.
·
Cell Death Discovery
·
5
PDF
CD38 prognostic role in chronic lymphocytic leukemia patients treated with standard chemotherapy or targeted agents: a monocentric real-life experience
2025
·
Laura Mettivier
, Danilo De Novellis
, et al.
·
Frontiers in Oncology
·
3
PDF
Treatment of Chronic ITP with Avatrombopag: A Multicentric Real-World Experience
2024
·
Mario Troiano
, Claudia Giordano
, et al.
·
Blood
·
1
PDF
Effective Neutralizing Antibody Response Against SARS-CoV-2 Virus and Its Omicron BA.1 Variant in Fully Vaccinated Hematological Patients
2023
·
Danilo De Novellis
, Veronica Folliero
, et al.
·
Clinical and Experimental Medicine
·
1
PDF
Inter-intra instrument comparison and standardization of a 10-color immunophenotyping for B and T cell non-Hodgkin lymphoma diagnosis and monitoring
2022
·
Marisa Gorrese
, Angela Bertolini
, et al.
·
Journal of Immunological Methods
·
1
Pb1995: Safety of Subcutaneous Daratumumab in Multiple Myeloma: a Retrospective Multi-center Real Life Experience
2022
·
D. De Novellis
, A. Carobene
, et al.
·
HemaSphere
·
1
Hemopoiesis and Immune Cell Perturbations during Venetoclax Plus Azacytidine Treatment in Acute Myeloid Leukemia
2021
·
Valentina Giudice
, Idalucia Ferrara
, et al.
·
Blood
·
1
Long-term outcomes of fixed-duration venetoclax–rituximab in relapsed/refractory chronic lymphocytic leukemia: impact of prior BTK inhibitor exposure and measurable residual disease in a multicenter real-world study
2026
·
Claudia Giordano
, Giuliana Farina
, et al.
·
Research Square
PDF
Bridging Trials and Real Life in Fixed‐Duration BTKi –Venetoclax for CLL : A Delphi‐Enhanced Synthesis Incorporating Artificial Intelligence ( AI ) Benchmarks
2026
·
Stefano Molica
, Mariano Lucignano
, et al.
·
European Journal Of Haematology
Plasma Elastase Screening in Hematological Disease Reveals Its Potential as a Diagnostic and Prognostic Biomarker in Hematological Malignancies
2026
·
Pasqualina Scala
, Anna Maria Della Corte
, et al.
·
International Journal of Laboratory Hematology
Rituximab maintenance in marginal zone lymphoma: Evidence from a real-world single center case series study
2026
·
Luca Pezzullo
, Lorenzo Settembre
, et al.
·
Bulletin du Cancer
Consensus on optimal use of fixed-duration BTK inhibitor and venetoclax therapy in CLL: A delphi study comparing human expertise and AI methodologies
2025
·
Giuliana Farina
, Mariano Lucignano
, et al.
·
Blood
PDF
Distinct immunologic kinetics and cytomegalovirus reactivation incidence with rituximab- versus obinutuzumab–bendamustine in follicular lymphoma: a single-center case series study
2025
·
Matteo D’Addona
, Luca Pezzullo
, et al.
·
Journal of Cancer Research and Clinical Oncology
PDF
CD38 Expression As an Additional Prognostic Marker in Mantle Cell Lymphoma
2024
·
Matteo D'Addona
, Luca Pezzullo
, et al.
·
Blood
PDF
P1531: Tixagevimab-cilgavimab Therapy in the Prevention of Sars-cov2 Infection in Non-hodgkin-b Lymphomas and Hodgkin Lymphomas Under Treatment: Our Experience
2023
·
Luca Pezzullo
, Valentina Giudice
, et al.
·
HemaSphere
P1544: Impact of Sars-cov 2 Infection, in Treated Nhl-b and Hd, After Vaccination and Preventive Therapy With Antibodies: Our Experience
2023
·
Luca Pezzullo
, Valentina Giudice
, et al.
·
HemaSphere
Tixagevimab‐cilgavimab Therapy in the Prevention of Sars‐cov2 Infection in Non Hodgkin‐b Lymphomas and Hodgkin Lymphomas Under Treatment: Our Experience
2023
·
L. Pezzullo
, V. Giudice
, et al.
·
Hematological Oncology
PDF
Negative Synergism Betwenn the Combination of Steroid and Low Molecular Weight Heparin (lmwh) on Bone Metabolism, in Patients Treated for Lymphoma
2021
·
L. Pezzullo
, M. D'Addona
, et al.
·
Hematological Oncology
PDF
Pet Oriented Intensification and Maintenance With Rituximab in First Line Non‐hodgkin Large B Cell Lymphoma (dlbcl)
2021
·
L. Pezzullo
, G. Cassiordor0
, et al.
·
Hematological Oncology
PDF
Prognostic value of interim PET in aggressive non Hodgkin lymphoma
2015
·
Luigi Aloj
, Ferdinando Frigeri
, et al.
·
Journal of Nuclear Medicine
Show more works
View as search
Works count:
35
Citation count:
77
H-index:
5
I10-index:
4
Year
Topic
Type